We serve Chemical Name:2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid CAS:100961-61-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid
CAS.NO:100961-61-3
Synonyms:2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid
Molecular Formula:C15H11NO2S2
Molecular Weight:301.38300
HS Code:2934200090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:513.3ºC at 760mmHg
Density:1.44g/cm3
Index of Refraction:
PSA:103.73000
Exact Mass:301.02300
LogP:4.28680
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid Use and application,2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid technical grade,usp/ep/jp grade.
Related News: Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid manufacturer Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. 2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid supplier The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid vendor Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. 2-(1,3-benzothiazol-2-ylsulfanylmethyl)benzoic acid factory The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed.
